OTC · ALPMY
Healthcare · Drug Manufacturers - General
$16.00
Down-$0.12 (-0.74%)
Updated Nov 5, 2026, 12:40 AM
SID Score
6.5/10
Composite research score
Smart Money
46/100
Neutral
Price performance · ALPMY
1M range · 0 trading sessions · Daily adjusted prices
ALPMY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning ALPMY.
Company
Market Activity
Research & News
ALPMY research
Company profile and research snapshot.
ASTELLAS PHARMA UNSP/ADR
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 28, 2026
Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.
Yahoo · Oct 28, 2026
Astellas pens this deal as it looks to offset the upcoming patent expiry of key portfolio medicine, Xtandi.
Yahoo · Oct 27, 2026
Astellas Pharma Inc. [TSE: 4503, President and CEO: Naoki Okamura, "Astellas"] and Audax Biosciences Pty Ltd ("Audax") today announced that they have entered into an exclusive option and license agreement for DAX-044, Audax's lead immuno-oncology AVIKINE® candidate. Under the agreement, Astellas receives an exclusive option which, on exercise, will grant Astellas a worldwide license to develop, manufacture and commercialize DAX-044. Audax has the option to co-fund and co-promote DAX-044 in Austr
Yahoo · Oct 26, 2026
Astellas Pharma Canada, Inc. today announced the presentation of new Canadian real-world evidence describing the implementation of biomarker testing and targeted treatment delivery for adults with CLDN 18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer. The data demonstrate the value of a national testing pathway through validated centres that enabled timely access to CLDN 18.2 biomarker testing and targeted treatment with z
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALPMY.
